CORZ
Core Scientific, Inc./tx Financials Finance Services Russell 3000
$13.25Close
$4.2BMarket cap
$13.10 – $29.1652-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 5 · weaker than 95% of stocks over 12 months
- Far from its high 55% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
55%
1wk
up 1.1%
price change
1mo
down 17.1%
price change
12-month return
down 36%
market up 11% ·
its own down 47%
F-score
4 / 9
Weak
Altman Z″
-6.45
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
10%
of the market · expensive
Revenue growth
down 38%
year on year
EPS growth
—
latest quarter
Sales growth
up 109%
latest quarter · +64 pts
ROE
—
return on equity
Free cash margin
—
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
8.1%
$1.08 a day · 2×ATR $11.09
RS
5 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
1.15
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Accounts declared unreliable The company told the SEC that previously issued financial statements should no longer be relied upon. Every figure on this page that predates that filing is drawn from statements the company itself has withdrawn.
- Liabilities exceed assets Shareholders' equity is negative at -$962.7M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 7.4% over the year, from 293m to 314m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 23.7% to 11.9%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 37.5% over the year, from $510.7M to $319.0M.
Last reported
Jul 28, 2026
Last shock
Oct 14, 2026-12% in one session2.4× volumeno filing matched-2% since
Financials
- Gross 12%
- Net -90%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $60.3M | $544.5M | $640.3M | $502.4M | $510.7M | $319.0M |
| Gross margin | 16% | 44% | 1% | 25% | 24% | 12% |
| Operating income | -$6.3M | $131.5M | -$2.1B | $9.0M | -$142.1M | -$245.6M |
| Net income | -$12.2M | $47.3M | -$2.1B | -$246.5M | -$1.4B | -$288.6M |
| Net margin | -20% | 9% | -335% | -49% | -282% | -90% |
| Earnings per share | -$0.08 | $0.20 | -$6.30 | -$0.65 | -$5.62 | -$0.91 |
| Cash | $8.7M | $117.9M | $15.9M | $50.4M | $836.2M | $311.4M |
| Long-term debt | — | $652.2M | $0 | $684.1M | $1.1B | $1.1B |
| Shareholders' equity | $89.2M | $1.3B | -$409.3M | -$596.9M | -$943.0M | -$962.7M |
| Shares outstanding | — | 271.58m | 375.23m | 386.88m | 292.61m | 314.23m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 28, 2026 | Quarterly ↗ | Jun 30, 2026 | 28d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Oct 24, 2025 | Quarterly ↗ | Sep 30, 2025 | 24d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 13, 2024 | Annual ↗ | Dec 31, 2023 | 73d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 10, 2026 | Regulation FD ↗ |
| Aug 27, 2026 | Material agreement · New obligation · Regulation FD ↗ |
| Aug 14, 2026 | Regulation FD · Other events ↗ |
| Jul 29, 2026 | Director or officer change · Regulation FD ↗ |
| Jul 28, 2026 | Results · Regulation FD ↗ |
| Jul 28, 2026 | Unregistered share sale · Regulation FD ↗ |
| May 26, 2026 | Director or officer change · Regulation FD ↗ |
| May 15, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results · Regulation FD ↗ |
| May 6, 2026 | Material agreement · Regulation FD ↗ |
| May 6, 2026 | Material agreement · Agreement ended · New obligation · Other events ↗ |
| May 5, 2026 | Director or officer change ↗ |